Journal
SCIENCE
Volume 316, Issue 5827, Pages 1039-1043Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1141478
Keywords
-
Categories
Funding
- NCI NIH HHS [1K12CA87723-01, R01-CA111560, P20CA90578-02, P01 CA089021, K08CA120060-01, R01CA114465-01] Funding Source: Medline
- NIGMS NIH HHS [R01 GM041890, GM41890] Funding Source: Medline
Ask authors/readers for more resources
The epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib are effective treatments for lung cancers with EGFR activating mutations, but these tumors invariably develop drug resistance. Here, we describe a gefitinib-sensitive lung cancer cell line that developed resistance to gefitinib as a result of focal amplification of the MET proto-oncogene. inhibition of MET signaling in these cells restored their sensitivity to gefitinib. MET amplification was detected in 4 of 18 (22%) lung cancer specimens that had developed resistance to gefitinib or erlotinib. We find that amplification of MET causes gefitinib resistance by driving ERBB3 (HER3)-dependent activation of PI3K, a pathway thought to be specific to EGFR/ERBB family receptors. Thus, we propose that MET amplification may promote drug resistance in other ERBB-driven cancers as well.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available